3/27
08:02 am
cgtx
Cognition Therapeutics (CGTX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
High
Report
Cognition Therapeutics (CGTX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
3/26
07:30 am
cgtx
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
Low
Report
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
3/23
07:40 am
cgtx
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results [Yahoo! Finance]
Medium
Report
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results [Yahoo! Finance]
3/23
07:30 am
cgtx
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Medium
Report
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
3/17
07:42 am
cgtx
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 [Yahoo! Finance]
Medium
Report
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 [Yahoo! Finance]
3/17
07:30 am
cgtx
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Medium
Report
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
3/2
08:01 am
cgtx
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis [Yahoo! Finance]
Low
Report
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis [Yahoo! Finance]
3/2
07:30 am
cgtx
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Low
Report
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
2/6
05:33 pm
cgtx
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Low
Report
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
2/5
07:30 am
cgtx
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Medium
Report
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
2/5
06:09 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
1/27
07:30 am
cgtx
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Medium
Report
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
1/6
07:47 am
cgtx
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]
Low
Report
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]
1/6
07:30 am
cgtx
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
Low
Report
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies